Studies suggest the short peptide Livagen, structurally similar to Epitalon (Epithalon), may potentially affect the immune system, gastrointestinal tract, and liver. It is hypothesized that Livagen, a peptide bioregulator, may have a direct effect on DNA and the expression of genes. The potential to activate genes in the gastrointestinal tract and immune system, which may become silenced owing to DNA condensation with aging, may be responsible for its purported anti-aging potential.

DNA in eukaryotic creatures seems to be organized hierarchically and more compactly. The DNA in a single cell may only take up a thousandth of a millimeter of space despite its almost three feet original size. Chromosomes are the packaged result of DNA's interaction with histone proteins, which create chromatin structures. In addition to aiding DNA replication and cell division, presumably accommodating genetic material inside cells, and controlling gene expression at a high level, this hierarchical arrangement is hypothesized to provide other potentially critical tasks. DNA packing and regulation of gene access seem to rely heavily on the structure of the DNA itself.

Livagen and Immunity

Studies looked into Livagen peptide, hypothesizing it might induce chromatin decondensation (unpacking) and activate many genes in lymphocytes (a main immune system cell type). Genes, such as ribosomal genes responsible for increased protein synthesis and cellular activity, that are generally silenced in mature and aged test mice are reactivated with this activation. As a result, Livagen may have a renewing impact on lymphocytes by directly affecting their DNA.

Lymphocytes are thought to include B and T cells, which play vital roles in the immune system. T cells seem to target sick or malignant cells, whereas B cells create antibodies to fight against foreign invaders. The cytokines secreted by T cells are thought to act as chemical signals that control inflammation and coordinate immune responses.

Decreased lymphocyte activity with age is hypothesized to increase susceptibility to various diseases. Findings from a research study by T Lezhava et al. propose that "these results indicate that peptide bioregulators Epitalon, Livagen, and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old individuals."

Livagen Peptide and the Heart

It is speculated that chromatin dysregulation may harm heart activity. Several studies have suggested that Livagen peptide, a bioregulatory peptide, may potentially reverse this chromatin dysregulation and protect the heart.

In a separate experiment, the potential of Livagen and cobalt ions on chromatin architecture were examined together. This combination, hypothesized to stimulate chromatin decondensation, appeared to successfully mitigate the consequences. It is claimed that the study's findings are significant "because it supplies new information about the protective effect of Livagen and Livagen + Cobalt ions on the lymphocytes of HCM [test subjects]."

Numerous studies suggest that lymphocytes' decondensation of chromatin, made possible by releasing certain genes, may help mitigate some of the long-term effects of cardiac problems. One proposed mode of action for Livagen is that it may alter the gene expression of lymphocytes, which might help reduce inflammation and the scarring it causes.

Livagen Peptide and Digestion

Recent studies suggest that when activated, mu and delta opioid receptors help maintain the GI tract's protective mucosal barrier. Possibly via boosting vagal nerve communication to the GI tract and by regulating mucosal nitric oxide and prostaglandins, Livagen may potentially have a considerable influence in this setting.

It seems that the sum of these systems provides substantial gastroprotection. It has been hypothesized that Livagen's potential to increase enkephalin levels in the circulation may greatly increase the activation of these receptors.

Livagen Peptide and Aging

Current studies suggest that changes in DNA organization may play a role in aging, affecting the accessibility and expression of certain genes. A leading expert on chromatin modifications in old age is Professor Teimuraz Lezhava, who has written extensively on the topic. As suggested by his findings, chromosomal abnormalities may grow with age. Chromatin condensation is a hallmark of these abnormalities and contributes to DNA inactivation and impaired cellular repair mechanisms.

The idea that counteracting chromatin condensation may theoretically increase longevity is fascinating. Since silencing genes seems to hasten aging, reactivating them could slow it down. Dr. Lezhava's findings suggest a few bioregulatory peptides may affect this process by decondensing DNA. These peptides include Livagen and Epitalon, among others.

Livagen Peptide and Pain

Some proteins called enkephalins seem to interact with mu and delta opioid receptors. Pain, blood pressure, and awareness seem to decrease with the activation of mu receptors, likewise targeted by morphine. Opiates cause respiratory depression; however, it is thought that this is partly due to the activation of delta receptors, which reduces pain perception. As suggested by animal studies of bioregulatory peptides, Enkephalin-degrading enzymes in the circulation may be inhibited by Livagen, leading to increased amounts of endogenous pain-relieving chemicals.


Studies suggest the short bioregulatory peptide Livagen may directly influence the DNA structure and function. Potentially increasing the expression of certain genes and fostering a more "youthful" cellular profile, this compound's most promising activity is hypothesized to be its potential to promote chromatin decondensation. Lymphocytes are crucial to the immune system and have been the primary subject of many studies. It is speculated that Livagen may play a pivotal role in immune system activation by modulating these cells. However, further study is needed to determine this peptide's full potential.

Scientists looking for research peptides for sale may find them at Core Peptides.


[i] Chromatin. National Human Genome Research Institute.

[ii] Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IY. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med. 2002 Oct;134(4):389-92. doi: 10.1023/a:1021924702103. PMID: 12533768.

[iii] Lymphocyte. National Human Genome Research Institute.

[iv] Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006 Apr;(133):111-5. PMID: 16705247.

[v] Dzhokhadze Ta et al., Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives), December 1, 2013.

Author's Bio: